Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Venclyxto
Venclyxto 10 mg film-coated tablets Venclyxto 50 mg film-coated tablets Venclyxto 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-135189 · Präparat HOS-097674
In a drug-drug interaction study in 12 healthy subjects, co-administration of 500 mg of azithromycin
on the first day followed by 250 mg of azithromycin once daily for 4 days decreased venetoclax Cmax
by 25% and AUC by 35%. No dose adjustment is needed during short-term use of azithromycin when
administered concomitantly with venetoclax.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T16:48:00Z · SHA-256 f5fb95bdf531b038e04eafc19a968401cedfe2f7ee06f04fa27184a292290e6e · Passage e35e5948a3be7cc77054cdeb6fe5bb16d08ec344211a14285406101955ce67b2 · Zeichen 3047–3386 im Abschnitt
Wechselwirkungen · Kisqali
Kisqali 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-136252 · Präparat HOS-097860
Anti-arrhythmic medicinal products and other medicinal products that may prolong the QT interval
Co-administration of Kisqali with medicinal products with a known potential to prolong the QT
interval such as anti-arrhythmic medicinal products (including, but not limited to, amiodarone,
disopyramide, procainamide, quinidine and sotalol), and other medicinal products that are known to
prolong the QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin,
ciprofloxacin, levofloxacin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide
and intravenous ondansetron) should be avoided (see section 4.4). Kisqali is also not recommended to
be used in combination with tamoxifen (see sections 4.1, 4.4 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) ciprofloxacin (HOS-085177) tamoxifen (HOS-088380) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) azithromycin (HOS-088112) levofloxacin (HOS-128837) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) pimozide (HOS-085600) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) ondansetron (HOS-086052) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:22:00Z · SHA-256 808e9743b462916472557a0fc0a032e5a4cdf4c2e48d8fd0f992823e92cc05c1 · Passage 58204aa4622d8004f93cd3949febb145336dedbece94dc5cc46a58898e28a2af · Zeichen 8724–9480 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-138708 · Präparat HOS-098240
Atovaquone/ Rilpivirine ↔
Proguanil/ (Not studied).
Rilpivirine
Macrolide antibiotics
Clarithromycin Dolutegravir Where possible, alternatives such as azithromycin
Erythromycin (Not studied) should be considered.
/Dolutegravir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atovaquone (HOS-086266) azithromycin (HOS-088112) proguanil (HOS-138707) clarithromycin (HOS-084517) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 22dc712222a236e2d7b971b20aa199dfd8eefacc91b043310e35b9afc0c124fc · Zeichen 26050–26370 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-139293 · Präparat HOS-098314
Voxilaprevir:
AUC: ↔
Cmin: ↔
Cmax: ↔
Antifungals
Voriconazole (300 mg twice daily), Bictegravir: No dose adjustment is required
Bictegravir1 AUC: ↑ 61% upon co-administration.
Cmax: ↔
(Inhibition of CYP3A)
Itraconazole Interaction not studied with any of
Posaconazole the components of Biktarvy.
Co-administration of itraconazole
(Inhibition of P-gp/BCRP) or posaconazole may increase
bictegravir plasma concentrations.
Macrolides
Azithromycin Interaction not studied. Caution is recommended due to the
Clarithromycin Co-administration of azithromycin potential effect of these medicinal
or clarithromycin may increase products on the bictegravir
(Inhibition of P-gp) bictegravir plasma concentrations. component of Biktarvy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) voriconazole (HOS-084524) voxilaprevir (HOS-108930) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage b4588db69f4f4c2fe2a8a36c67b782785132ecf734ae6470ad5143dde0d39e0f · Zeichen 9817–11027 im Abschnitt
Wechselwirkungen · Xospata
Xospata 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-141410 · Präparat HOS-098642
CYP3A, P-gp and/or BCRP inhibitors
Strong inhibitors of CYP3A, P-gp and/or BCRP (e.g., voriconazole, itraconazole, posaconazole,
clarithromycin, erythromycin, captopril, carvedilol, ritonavir, azithromycin) can increase gilteritinib
plasma concentrations. A single, 10 mg dose of gilteritinib co-administered with itraconazole (200 mg
once daily for 28 days), a strong CYP3A, P-gp and BCRP inhibitor, to healthy subjects resulted in an
approximate 20% increase in mean Cmax and 2.2-fold increase in mean AUCinf relative to subjects
administered a single dose of gilteritinib alone. Gilteritinib exposure increased approximately 1.5-fold
in patients with relapsed or refractory AML when co-administered with a strong CYP3A, P-gp and/or
BCRP inhibitor (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): captopril (HOS-085478) carvedilol (HOS-115322) azithromycin (HOS-088112) voriconazole (HOS-084524) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:12:00Z · SHA-256 c553334e12e70f11f6e5ebf231d99102b822bac3002cf0bd26bc31c72e26836b · Passage 41d2074bca95d47bf686b06bba6001dbcad79c2302143c825f3f7dbca7701f26 · Zeichen 710–1478 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-146511 · Präparat HOS-099534
Clinical interaction studies with P-gp inhibitors (erythromycin and azithromycin) and
combined P-gp and strong CYP3A4 inducers (rifampicin) have shown to affect the exposure
of relugolix to a clinically relevant extent. Effect of co-administration on the exposure to
4
relugolix and associated dosing recommendations are summarised in Table 1. This list also
includes expected effect and recommendations with other potentially interacting medicinal
products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage f2a5e41c2adef76002acb349471aa6232b57dfcea60681bb3620f58bc30dcc60 · Zeichen 76–582 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-146532 · Präparat HOS-099534
Medicinal products that are oral P gp inhibitors
erythromycin 120 mg 3.5 -fold ↑ 2.9 -fold ↑ Concomitant use of
single dose Orgovyx with
500 mg QID, multiple erythromycin,
doses azithromycin and
other oral P-gp
(P-gp and moderate inhibitors is not
CYP3A4 inhibitor) recommended
azithromycin 120 mg *1.5 -fold ↑ *1.6 -fold ↑
single dose If concomitant use
500 mg single dose with once or twice
daily oral P-gp
(P-gp inhibitor) inhibitors is required
(e.g. azithromycin),
azithromycin 1.4 -fold ↑ 1.3 -fold ↑ take Orgovyx first,
and separate dosing
500 mg single dose 6 with the P-gp
hours inhibitor by at least 6
hours and monitor
after administration of patients more
relugolix frequently for
adverse reactions.
(P-gp inhibitor)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage fcd454403f2d9350410b5a8c00ed4d280aa92451fc69fc9e389afa15d938e4dd · Zeichen 2704–4692 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-146533 · Präparat HOS-099534
Other medicinal Therapeutic Expected: ↑ Expected: ↑
products that are P-gp dose for
inhibitor include (but Orgovyx
not limited to):
See also See also
clinical study clinical study
Anti infectives
results with results with
azithromycin,
erythromycin erythromycin
erythromycin,
and and
clarithromycin,
azithromycin azithromycin
gentamicin,
(above). (above).
tetracycline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tetracycline (HOS-115153) azithromycin (HOS-088112) clarithromycin (HOS-084517) erythromycin (HOS-084514) gentamicin (HOS-091173)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage e51cb3d6445377f6c76e17084a83a2975079441f36a2d1410bf0888a148b4682 · Zeichen 4695–5426 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-146560 · Präparat HOS-099534
Medicinal products Therapeutic Expected: ↓ Expected: ↓
that are combined P dose for
gp and strong Orgovyx
CYP3A4 inducers
See also See also
include (but not
clinical study clinical study
limited to):
results with results with
erythromycin erythromycin
Androgen receptor
and and
inhibitor
azithromycin azithromycin
apalutamide.
(above). (above).
Anticonvulsants
carbamazepine,
phenytoin,
phenobarbital.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) apalutamide (HOS-086212) azithromycin (HOS-088112) erythromycin (HOS-084514) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage a07a2ea6a5a41db1ba835a1904f76bbe460b63c6b3f4952ecd4ba8f554cffe62 · Zeichen 8301–9021 im Abschnitt
Wechselwirkungen · Orgovyx
Orgovyx 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-146582 · Präparat HOS-099534
*: Upon co-administration of azithromycin and relugolix, relugolix exposure increases up to
5-fold were observed in the first 3 hours after dosing in the median concentration-time curves.
After a dose separation window of 6 hours, the increase in relugolix exposure in the median
concentration-time curves was maximally 1.6-fold in the first 3 hours after dosing.
10
Potential for relugolix to affect the exposure to other medicinal products
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T16:34:00Z · SHA-256 83d5275c068e4da33497bf48ce37dfa4eca293d7cd335add5247289a5323daa8 · Passage 3ac0fcc4809a1439168f802c5c1099126552e659570d2b0c95e1a64d504b6a3a · Zeichen 15988–16476 im Abschnitt
Wechselwirkungen · Etcamah
Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-153231 · Präparat HOS-100955
Camizestrant in combination with ribociclib has been studied clinically, a non-fatal Torsades de
Pointes was observed in a patient with bradycardia and QTc prolongation for camizestrant in
combination with ribociclib. It is recommended to monitor patients clinically and adjust doses as
specified in the approved ribociclib SmPC. Co-administration of other medicinal products known to
prolong the QT interval and/or have a known risk of Torsades de Pointes (e.g. ciprofloxacin,
levofloxacin, ondansetron, escitalopram, venlafaxine, fluconazole, chloroquine, halofantrine,
clarithromycin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, and pimozide) should
be avoided. If concomitant use cannot be avoided, monitor ECGs as clinically indicated (see section
4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) ciprofloxacin (HOS-085177) bepridil (HOS-085612) venlafaxine (HOS-086573) halofantrine (HOS-085606) azithromycin (HOS-088112) levofloxacin (HOS-128837) fluconazole (HOS-087945) clarithromycin (HOS-084517) pimozide (HOS-085600) moxifloxacin (HOS-085604) ribociclib (HOS-109454) camizestrant (HOS-153187) haloperidol (HOS-085602) ondansetron (HOS-086052) escitalopram (HOS-129417) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage ce564d7e55982dc12152f2fbc04e0ebba5b06ca87263436e7452cbf8d84c3813 · Zeichen 6458–7234 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.